Newcomers on the pharma M&A scene in 2007 include several Japanese buys in USA
2007 saw no mega merger and acquisition activity in the pharmaceutical and biotechnology sectors, but some interesting moves from Japanese, Indian and Chinese firms. Taking into account the transactions that specified financial terms, the total value of acquisitions was $101.21 billion, slightly down on 2006, when the figure was $106.32 billion (Marketletter Jan 1 & 8, 2007). For the full list of acquisitions in 2007 see pages 24-25.
It is difficult to say which was the biggest deal of 2007, since AstraZeneca's $15.6 billion purchase of MedImmune seems to be topped by the Schering-Plough's agreement to acquire the Dutch Organon business which, when first announced, was valued at around $14.4 billion versus the 11.0 billion-euro bid, a figure which increased to $15.99 billion euros on exchange rates when it was finally completed. Also, Merck KGaA's $14.6 billion acquisition of Swiss firm Serono closed in 2007.
Advent of mega licensing deals
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze